These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 6604099)

  • 1. Alternative pathway of complement activation by human lymphoblastoid B and T cell lines.
    Praz F; Lesavre P
    J Immunol; 1983 Sep; 131(3):1396-9. PubMed ID: 6604099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of the alternative complement pathway by human B cell lymphoma lines is associated with Epstein-Barr virus transformation of the cells.
    McConnell I; Klein G; Lint TF; Lachmann PJ
    Eur J Immunol; 1978 Jul; 8(7):453-8. PubMed ID: 211040
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CR2 is the primary acceptor site for C3 during alternative pathway activation of complement on human peripheral B lymphocytes.
    Marquart HV; Svehag SE; Leslie RG
    J Immunol; 1994 Jul; 153(1):307-15. PubMed ID: 7515925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of the alternative complement pathway by EBV and the viral envelope glycoprotein, gp350.
    Mold C; Bradt BM; Nemerow GR; Cooper NR
    J Immunol; 1988 Jun; 140(11):3867-74. PubMed ID: 2836501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alternative pathway of complement activation by stimulated T lymphocytes. II. Elevation of cytotoxic potential against complement receptor-carrying cell lines.
    Ramos OF; Sármay G; Eggertsen G; Nilsson B; Klein E; Gergely J
    Eur J Immunol; 1987 Jul; 17(7):975-9. PubMed ID: 3111863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lymphocytes stimulated by allogeneic B cell lines cleave the third component of complement and fix C3 fragments. Their nonspecific lytic capacity is elevated against complement receptor type 2-carrying targets.
    Ramos OF; Algarra I; Sármay G; Yefenof E; Gergely J; Klein E
    J Immunol; 1989 Jan; 142(1):217-23. PubMed ID: 2521233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Production of nephritic factor of the alternative complement pathway by Epstein Barr virus-transformed B cell lines derived from a patient with membranoproliferative glomerulonephritis.
    Hiramatsu M; Balow JE; Tsokos GC
    J Immunol; 1986 Jun; 136(12):4451-5. PubMed ID: 3011894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CR2 is a complement activator and the covalent binding site for C3 during alternative pathway activation by Raji cells.
    Mold C; Nemerow GR; Bradt BM; Cooper NR
    J Immunol; 1988 Mar; 140(6):1923-9. PubMed ID: 2831273
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alternative pathway of complement activation by stimulated T lymphocytes. I. Binding of C3 fragments.
    Sármay G; Ramos OF; Klein E; Kai C; Gergely J
    Eur J Immunol; 1987 Jul; 17(7):969-74. PubMed ID: 3111862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of the alternative complement pathway by normal and transformed cells in homologous and heterologous sera.
    McConnell I; Gorman NT; Raniwalla J; Powell P
    Eur J Immunol; 1981 Feb; 11(2):126-32. PubMed ID: 6260511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human B lymphocytes activated by Epstein-Barr virus (EBV) or by mitogens suppress mitogen-induced immunoglobulin production.
    Tsukuda K; Berczi I; Klein G
    J Immunol; 1981 May; 126(5):1810-3. PubMed ID: 6260858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Surface immunoglobulins are involved in the interaction of protein A with human B cells and in the triggering of B cell proliferation induced by protein A-containing Staphylococcus aureus.
    Romagnani S; Giudizi MG; Biagiotti R; Almerigogna F; Maggi E; Del Prete G; Ricci M
    J Immunol; 1981 Oct; 127(4):1307-13. PubMed ID: 6974188
    [TBL] [Abstract][Full Text] [Related]  

  • 13. C3 synthetic peptides support growth of human CR2-positive lymphoblastoid B cells.
    Servis C; Lambris JD
    J Immunol; 1989 Apr; 142(7):2207-12. PubMed ID: 2784456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of gangliosides on activation of the alternative pathway of human complement.
    Michalek MT; Bremer EG; Mold C
    J Immunol; 1988 Mar; 140(5):1581-7. PubMed ID: 3346542
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic alterations associated with proliferation of mitogen-activated lymphocytes and of lymphoblastoid cell lines: evaluation of glucose and glutamine metabolism.
    Brand K; Leibold W; Luppa P; Schoerner C; Schulz A
    Immunobiology; 1986 Oct; 173(1):23-34. PubMed ID: 3492437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel mechanism of alternative pathway complement activation accounts for the deposition of C3 fragments on CR2-expressing homologous cells.
    Schwendinger MG; Spruth M; Schoch J; Dierich MP; Prodinger WM
    J Immunol; 1997 Jun; 158(11):5455-63. PubMed ID: 9164968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro complement activation by rabbit lymphocytes and thymocytes in autologous serum.
    Wilson AB; Lachmann PJ; Coombs RR
    Immunology; 1979 May; 37(1):25-34. PubMed ID: 112041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. B lymphocytes and macrophages release cell membrane deposited C3-fragments on exosomes with T cell response-enhancing capacity.
    Papp K; Végh P; Prechl J; Kerekes K; Kovács J; Csikós G; Bajtay Z; Erdei A
    Mol Immunol; 2008 Apr; 45(8):2343-51. PubMed ID: 18192019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hybrid cells formed by fusion of Epstein-Barr virus-associated B-lymphoblastoid cells and either marrow-derived or solid tumour-derived cell lines display different co-stimulatory phenotypes and abilities to activate allogeneic T-cell responses in vitro.
    Cywinski AL; Dunnion DJ; Teobald I; Tucker VC; Browning MJ
    Tissue Antigens; 2006 Aug; 68(2):115-26. PubMed ID: 16866881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective and efficient inhibition of the alternative pathway of complement by a mAb that recognizes C3b/iC3b.
    DiLillo DJ; Pawluczkowycz AW; Peng W; Kennedy AD; Beum PV; Lindorfer MA; Taylor RP
    Mol Immunol; 2006 Mar; 43(7):1010-9. PubMed ID: 15961157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.